SFA Therapeutics

Our CEO, Ira Spector, Ph.D., discussed his journey into drug development and his mission to address disease progression, not just symptoms, with Jeff Harmon of Conversations Life Science Leaders Aren’t Having. Listen here: https://lnkd.in/eCxUqJHY

Our CEO, Ira Spector, Ph.D., will be presenting at the MedInvest Biotech & Pharma Investor Conference, taking place in New York City on September 18-19. https://lnkd.in/dusxNE3 #Biotech #Pharma #LifeSciences

In the first episode of season eight of Conversations Life Science Leaders Aren't Having Podcast, host Jeff Harmon welcomes Ira Spector, CEO of SFA Therapeutics, a biotech startup focused on revolutionary treatments for chronic inflammatory diseases. Ira provides a fascinating look into his company's innovative approach to using substances from the GI microbiome to develop immunomodulating drugs. This episode is a thought-provoking exploration of leadership in biotech and the life sciences, as well as a call to action for innovation in drug development. Ira also discusses the mindset shift needed in the biotech industry. He advocates for a move away from treating symptoms toward addressing the root causes of diseases, something that he believes is crucial for the future of medicine. The Conversations Life Science Leaders Aren't Having Podcast is LIVE today on Spotify, Apple Podcasts, and YouTube. Links in the first comment below.

Our CDO, Alla Arzumanyan, Ph.D., and our COO, James Kirwin, will be presenting at Life Sciences Pennsylvania. We look forward to sharing our insights and connecting with other fellow industry leaders in Pennsylvania. https://lnkd.in/ekKqhBg #Biotech #LifeSciences #Pharma

SFA Therapeutics will be participating in two conferences next week: Life Sciences Pennsylvania and MedInvest Biotech & Pharma Investor Conference. Keep an eye out for more details. https://lnkd.in/ekKqhBg https://lnkd.in/dusxNE3

We are eager to welcome Dr. Ananda Gubbi to our team as Director of #Biostatistics! With 25+ years of experience, Dr. Gubbi has guided various #biotech and #pharma firms through preclinical to Phase IV studies, leading 9 successful FDA submissions. “Dr. Gubbi’s technical expertise in the analysis of clinical trial data along with his experience in drug development will be valuable for SFA Therapeutics as we progress SFA-002 and other therapeutic candidates through the clinic,” said Dr. Ira Spector, Chief Executive Officer of SFA Therapeutics. Learn more here: https://lnkd.in/gG45WtHw

Mild to moderate psoriasis presents two significant challenges. 1. It can serve as a precursor to more severe forms of psoriasis and other related conditions. 2. There is a treatment gap for moderate psoriasis, as most available therapies are designed for moderate to severe cases. With SFA-002, we aim to prevent disease progression and address the current gaps in treatment. https://lnkd.in/eNgvJW8k

Last month, we announced James Kirwin as our new COO. Thanks so much to pharmaphorum for highlighting our exciting leadership news! His extensive operations experience is invaluable as we advance our mission to develop innovative treatments for #chronic #inflammatory diseases. https://lnkd.in/eKxit46j

We had a great time at #AADinnovation2024 last week. We met with so many innovators with groundbreaking ideas and advancements in the dermatology space, and we are eager to bring this positive energy into the rest of the year! https://lnkd.in/ertytZdj #clinicaltrials #dermatology #innovation

#ICYMI – James Kirwin recently joined our team as our Chief Operating Officer. He is a seasoned biopharma clinical operations executive and has a proven track record of success with global industry leaders Pfizer, Wyeth, and AstraZeneca. Read more here: https://lnkd.in/eBkbmUFx